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Abstract  
Aims: Closed-loop insulin delivery has the potential to improve day-to-day glucose control in 
Type 1 diabetes pregnancy. However, the psychosocial impact of day-and-night usage of 
automated closed-loop systems during pregnancy is unknown. Our aim was to explore 
women’s experiences and relationships between technology experience and levels of trust in 
closed-loop therapy.   
 Methods: We recruited 16 pregnant women with Type 1 diabetes to a randomised crossover 
trial of sensor-augmented pump therapy compared to automated closed-loop therapy. We 
conducted semi-structured qualitative interviews at baseline and follow-up. Findings from 
follow-up interviews are reported here.  
Results: Women described benefits and burdens of closed-loop systems during pregnancy. 
Feelings of improved glucose control, excitement and peace of mind were counterbalanced 
by concerns about technical glitches, CGM inaccuracy and the burden of maintenance 
requirements. Women expressed varied but mostly high levels of trust in closed-loop therapy. 
Conclusions: Women displayed complex psychosocial responses to day-and-night closed-
loop therapy in pregnancy. Clinicians should consider closed-loop therapy not just in terms of 
its potential impact on biomedical outcomes but also in terms of its impact on users’ lives. 
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Introduction 
Pregnant women with Type 1 diabetes experience higher rates of foetal, maternal and neonatal 
complications than the general maternity population of women without diabetes [1-5]. In 
England, structured antenatal care for women with pregestational diabetes involves frequent 
clinical contact (typically every 1-2 weeks) with specialist diabetes pregnancy health care 
teams. Together with strict glucose control before and during pregnancy, this care model allows 
treatment to be individually tailored to address physiological changes and can thus minimise 
diabetes-related risks during pregnancy [5-7]. As a result of the potential consequences of 
hyperglycaemia, many women with Type 1 diabetes are highly motivated to improve their self-
care routines (e.g. dietary intake, insulin dose adjustment, and glucose monitoring) during the 
course of their pregnancy.  
Nevertheless, a recent cohort study in the UK found that only 16% and 40% of women in early 
and late Type 1 pregnancy respectively met HbA1c targets of <6.5% [7]. The combination of 
sustained intensive effort and the difficulty of achieving optimal outcomes can impact 
negatively upon women’s psychosocial wellbeing by adding to existing cognitive and 
emotional burdens arising from continued self-care [8-9]. Consequently, significant clinical 
and research effort has focused on the potential contribution of diabetes technologies in terms 
of minimising self-care burdens and maximising positive outcomes. Recent studies have 
demonstrated benefits arising from the use of continuous glucose monitoring (CGM) and 
continuous subcutaneous insulin infusion (CSII), or insulin pumps, in selected patient groups 
during pregnancy [10-12]. CONCEPTT, a large multicentre randomised controlled trial of real-
time CGM, found that pregnant women using CGM spent an additional 100 min per day in the 
recommended control range and experienced significant reductions in the rate of large for 
gestational age birthweight and other neonatal outcomes.[10] CGM data can also provide 
detailed information on glucose pathophysiology, helping women with diabetes and clinicians 
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to target insulin delivery with CSII (i.e. sensor-augmented pump therapy) or multiple daily 
injections (MDI) to avoid the risk of neonatal complications such as neonatal hypoglycaemia 
and neonatal intensive care unit admission, albeit by requiring extensive commitment from 
users and healthcare professionals.[11]  
In terms of CSII, there are no contemporary randomised controlled trial data. Kallas-Koeman 
et al performed a cohort study comparing CSII and MDI in pregnancy, finding lower HbA1c 
levels in CSII than MDI across all trimesters of pregnancy.[12] The National Pregnancy in 
Diabetes (NPID) audit found that insulin pump users were more likely to achieve HbA1c levels 
during the first trimester.[7] However, another study found no significant difference in HbA1c 
between CSII and MDI.[13] These studies are all subject to important confounders such as 
indications for pump therapy, with outcomes dependent on patient and healthcare professional 
training and competency with insulin dose adjustment, which is arguably more complex with 
pump use. More widely, a recent review of technology in diabetes pregnancy highlighted 
uncertainty regarding the benefits of pump usage in terms of HbA1c and pregnancy 
outcomes.[5]  
Closed-loop systems represent the latest stage in diabetes technology evolution, building on 
established technologies such as CGM and CSII but seeking to reduce the cognitive burdens 
required for effective use of sensor-augmented pump therapy. Closed-loop systems utilise 
control algorithms to provide automated, CGM-responsive basal insulin delivery via an insulin 
pump every 10-15 minutes [14]. These systems are often described as ‘hybrid’ systems rather 
than fully-automated systems because they require carbohydrate counting and manually 
administered pre-meal boluses. Nevertheless, they assume a substantial burden of basal insulin 
adjustment between meals and overnight compared to user-administered sensor-augmented 
pump therapy, arguably the best available alternative. Recent trials have demonstrated the 
safety of closed-loop, and its potential to improve glucose control in Type 1 diabetes pregnancy 
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without increasing maternal hypoglycaemia [15-16], but less is known about its psychosocial 
impact. Our aim in this study was to build on a previous psychosocial study of perceived 
benefits and burdens of overnight closed-loop therapy in pregnancy [17] by exploring pregnant 
women’s experiences of day-and-night automated closed-loop therapy, in addition to women’s 
levels of overall trust in closed-loop therapy. To the best of our knowledge, this is the first 
study to report psychosocial responses to day-and-night closed-loop therapy in type 1 diabetes 
pregnancy. 
 
Research Design and Methods 
We performed an open-label, randomised, crossover trial of a closed-loop system (Florence 
D2a, University of Cambridge) incorporating both biomedical outcomes and psychosocial 
evaluations. Full details of the study design, including sample size, power calculations and 
biomedical outcomes, have been previously reported [16]. After 2-4 weeks of device training, 
women were assigned randomly to either 4 weeks of day-and-night closed-loop or 4 weeks of 
user-directed sensor-augmented pump therapy, with a 2-week washout between study phases. 
Pre-meal boluses were manually administered using the study pump (DANA Diabecare R 
Insulin Pump SOOIL) bolus calculator in both phases.  
During closed-loop, an adaptive computer algorithm (University of Cambridge, version 
0.3.41p) housed on an Android mobile phone (Samsung Galaxy S4, Samsung, South Korea) 
used CGM glucose values (FreeStyle Navigator 2, Abbot Diabetes Care, Alameda, CA, USA) 
to calculate an appropriate basal insulin dose, which was delivered via an insulin pump every 
12 minutes. After the trial, women could opt to resume their previous intensive insulin regimen 
or continue using any combination of study devices through pregnancy and delivery and up to 
6 weeks post-partum.  
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We recruited nineteen participants between 18-45 years of age with HbA1c level between 6.5-
10% and between 8-24 weeks’ gestation from three U.K. National Health Service sites. We 
consciously enrolled a broad patient population with varied technology experience, diabetes 
education, and prior glycaemic control as measured by HbA1c. Key exclusion criteria were 
multiple pregnancy and severe physical or psychiatric co-morbidity. Three participants 
withdrew for varied reasons (dislike of study pump, mental health deterioration, pregnancy 
complications). Sixteen participants completed the randomised crossover trial. All were using 
intensive insulin therapy administered either by multiple daily injections (n=8) or CSII (n=8) 
before pregnancy. Six participants had previous experience of CGM. Over half had suboptimal 
booking HbA1c levels (>7.5%).  
Qualitative Interviews 
We administered semi-structured interviews according to a topic guide developed from 
reviewing relevant literature (Supplementary Materials). We interviewed women twice, at 
baseline during device training (T1) and following completion of the study (T2). This study 
reports findings from 16 T2 interviews focusing on participants’ experiences of closed-loop 
therapy, with individual participants numbered P1, P2, etc. In line with previous qualitative 
interview studies [18], we found this sample sufficient to attain data saturation (i.e. the point 
in data collection when no new data are found to develop emerging conceptual themes).  
Interviews were digitally recorded and transcribed verbatim. Interview transcripts were coded 
using NVivo software (QSR International Pty Ltd., Version 10, 2012, Cheshire, UK). We 
identified key themes relating to the burdens and benefits of diabetes technology using a 6-
stage thematic analysis approach [19]. Our approach was informed by theories of sensemaking, 
according to which technology experience is influenced by users’ preceding experiences, 
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attitudes and values in conjunction with technological ‘affordances’, or actions and capacities 
that technology allows or ‘affords’ [20]. 
Results 
Benefits of closed-loop therapy  
Table 1 presents in summary form the benefits that interviewees reported from their experience 
of closed-loop therapy, presented in order of number of participants mentioning each perceived 
benefit and with a range of alternate keywords provided by participants (see Supplementary 
Materials for further illustrative quotations regarding both benefits and burdens). The most 
frequently mentioned benefit (N=14) related to the peace of mind that users gained by using 
closed-loop therapy, e.g.: ‘[I]t’s very freeing. A lot less, kind of, thought went into organising 
my diabetic insulin ratios, and so that’s kind of handed over to the technology, which was really 
good’ (P10). A related perceived benefit, mentioned by 9 women, emphasised the increased 
flexibility of lifestyle during pregnancy with diabetes due to greater convenience, fewer 
fingerpricks, and increased ease of dietary planning: ‘It was easier to maintain with eating… I 
knew that even if my blood sugar did pick up a little bit after a meal then it would correct itself’ 
(P5). 
Interviewees also emphasised technological benefits of the closed-loop system, including 
positive attitudes to the system’s smartphone interface (N=11) and excitement at experiencing 
cutting-edge technology (N=12): ‘It’s kind of amazing that the technology is there. I find that 
quite exciting’ (P11). With regard to the glycaemic control they experienced while using the 
system, 12 women expressed significantly positive opinions, e.g.:  
 [I]t all works so well, yeah, I was never kind of really worried about what my blood 
sugars were… I always knew that the best way to bring my blood sugars under control 
was actually to leave well alone and let the system do it.   P16 
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A number of participants mentioned benefits related specifically to CGM use, including 
reassurance arising from the ability to access continuously updated data on glucose levels 
(N=9) and new insights regarding bodily response to diet, exercise, stress, and pregnancy 
(N=9). Smaller numbers of women discussed further benefits, including the utility of system 
alarms (N=7) and insulin pump (N=6), improved sleep (N=5), and perceived ease of operation 
(N=3). Additionally, several individuals (N=5) described positive experiences of incorporating 
study devices into their bodily sensations: ‘I’ve kind of come to terms with, personally, like 
being bionic, having a thing attached to me’ (P1).  
 
TABLE 1 ABOUT HERE 
 
 
Burdens of closed-loop therapy   
By comparison with perceived benefits, participating women mentioned a wider range of 
perceived burdens (as presented in Table 2). 100% of participants highlighted technical glitches 
with the closed-loop system in general, such as connectivity problems and reversion to ‘open-
loop’ (non-algorithmic sensor-augmented pump therapy), while 87.5% (N=14) of participants 
emphasised technical challenges experienced specifically with CGM-related parts of the 
system, such as sensor insertion challenges, calibration difficulties, and inaccuracy: ‘For more 
than half of the time the CGM has been slightly out of synch with the reality of my blood 
glucose levels’ (P2). 
A number of women who mentioned particular benefits also mentioned countervailing burdens. 
In addition to technical glitches (both CGM and non-CGM) weighing against general 
perceptions of (e.g.) peace of mind and excitement at new technology, women’s specific 
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complaints such as those regarding system bulk (N=13), onerous maintenance requirements 
(N=12), system alarms (N=11) and the need for pre-prandial bolusing (N=7) seem to work 
against widely-shared perceptions of flexible lifestyles, improved sleep, and the utility of 
system alarms. Despite 75% of women also identifying good control as one of the perceived 
benefits of closed-loop (Table 1), 50% of participants criticised the system algorithm as being 
overly cautious and leading to suboptimal glycaemic control, e.g.: 
[W]hen you’re on that phone system, like, it won’t let you correct as easily.  So 
sometimes if you are high, you just have to sit there and wait for the phone to realise 
and then bring you down, which may take two hours.   P9 
 
Additional perceived burdens included difficulties arising from system pump usage (N=7), 
system visibility (N=7), adhesive problems (N=5), and anxiety arising from system use (N=4), 
as well as smaller numbers of women identifying challenges relating to exercise, addictiveness, 
‘deskilling’ as a consequence of system usage, and dislike of the smartphone interface. Five 
interviewees also discussed initial challenges associated with surrendering control of diabetes 
to technology, with one woman remarking that ‘[i]t was really scary, the idea of handing 
[control] over to something else was quite frightening’ (P13).  
Levels of Trust  
These complex experiences of closed-loop therapy led to varied levels of trust in closed-loop 
therapy. When asked to estimate the level of trust they placed in the system, seven women gave 
percentage figures ranging between 80% and 100% with a mean of 89.9%, indicating high 
levels of trust in closed-loop therapy. The remaining women gave verbal answers (i.e. answers 
without a percentage figure) that encompassed a range of opinions, with four participants 
expressing similarly high levels of trust to the women mentioned above (e.g. ‘I would say [I 
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trusted it] totally’, P12) and five participants framing their responses with a range of caveats. 
These included the view that trust has to be accompanied by continued vigilance (‘You can’t 
just leave it… I do trust it but… you do have to keep checking’ [P11]); the view that trust 
developed only during the post-study period (‘Now I do [trust it] but during the four-week 
[study] period I didn’t’ [P2]); and the view that system inaccuracy means that ‘reliability’ may 
be a more appropriate term than ‘trust’: ‘I might talk about reliability more than trust? It is 
really good. It’s just, not as accurate as you’d like it to be’ (P1).  
Discussion 
Building on a previous study of overnight closed-loop therapy in pregnancy [17], our findings 
provide the first insights into the complex psychosocial experiences of women using day-and-
night closed-loop therapy in pregnancy. Our findings indicate a range of perceived benefits, 
reflected by all participants opting to continue using closed-loop for at least some of the time 
after the randomized trial and 12 of 16 participants continuing to use closed-loop post-partum 
[16]. While our data indicate that closed-loop is in many ways a positive technological 
experience with potential to mitigate the significant burdens of self-care in pregnancy, they 
also show that users’ positive perceptions were counterbalanced by a range of less positive 
experiences, leading to an overall picture of complexity and ambivalence. 
Our key findings relate, first, to the balance between perceived benefits (e.g. peace of mind, 
excitement at new technology, and impressions of superior glycaemic control) on the one hand, 
and perceived burdens (e.g. technical glitches, system bulk, and suboptimal algorithmic 
control) on the other. We thus confirm the findings of several previous psychosocial studies of 
closed-loop systems that have reported the co-existence of multiple perceived benefits and 
burdens in a range of populations and study contexts [17,21-25]. Our data also echo the co-
existence of perceived benefits and burdens reported in our previous study of overnight usage, 
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although some perceived burdens identified in that study (e.g. obsessive checking of system 
readouts, concerns regarding ‘deskilling’ arising from loss of bodily sensation or ‘outsourcing’ 
sensation to system devices) did not emerge as strongly in the present study. It is possible that 
the more extended usage entailed by day-and-night usage may have led to a decline in 
obsessiveness as the novelty of the system wore off over time (as is common with wearable 
technologies in general [26]). It is unclear why deskilling concerns should have been more 
prominent in the previous study, although the broader population enrolled in this study (with 
concomitant variations in booking HbA1c and prior technology usage) may have included 
fewer women who were highly aware of diabetes-related bodily sensations and therefore the 
related possibilities of technology-related deskilling and ‘outsourcing’. 
A second key area of our findings relates to users’ views regarding the level of trust they placed 
in the study closed-loop system. Despite enumerating more perceived burdens than perceived 
benefits, participants generally expressed high levels of trust in the system. This finding was 
surprising in light of women’s widely-shared concerns about perceived burdens arising from 
technical glitches and other challenges, but could be related to prominent feelings of excitement 
at using new technology, superior glycaemic control, and peace of mind. A minority of women, 
however, expressed more qualified views, suggesting for instance that trust has to be 
counterbalanced with constant vigilance to ensure that the system is operating correctly. This 
variation in terms of women’s level of trust, and varied experiences more widely, may arise in 
part from the fact that contemporary closed-loop systems incorporate multiple interconnected 
devices: insulin pump, CGM sensor and transmitter, and smartphone. Each of these has its own 
distinct attributes and ‘affordances’ which may interact with individual users’ preferences and 
experiences in varied ways [27]. For example, participants were divided in terms of whether 
they regarded the DANA study pump in terms of perceived benefit (N=6) or perceived burden 
(N=7).  
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The strengths of this study include our use of semi-structured interviews to generate rich 
qualitative psychosocial data regarding experiences of technology use within a broad patient 
population, as part of a wider study generating detailed biomedical data about women’s 
response to closed-loop therapy in Type 1 diabetes pregnancy [16]. We are of course limited 
by the small number of participants and the fact that this was the first home study of day-and-
night closed-loop therapy in pregnancy, which may have contributed to women’s excitement 
and positive perceptions. 
Conclusions 
While future technological progress may alleviate specific concerns regarding technical 
glitches and physical bulk of closed-loop systems, other potential challenges such as 
maintenance requirements, human input needs (in terms of e.g. prandial bolusing), and 
surrendering control to technology may be more enduring features of automated diabetes 
technologies. When engaging with users who may exhibit both positive and negative 
impressions of new technologies, clinicians will need to take account of these psychosocial 
factors to manage expectations and use technology appropriately. Consequently, clinicians 
should consider closed-loop therapy not just in terms of its potential impact on biomedical 
outcomes but also in terms of its potentially varied impact in the complex and varied contexts 
of individual users’ lives. New diabetes technologies should not be introduced without 
appropriate innovations in terms of surrounding clinical care. Significant clinical training, 
engagement and investment may be necessary in order to minimise the burdens and maximise 
the benefits of future closed-loop systems in mainstream diabetes care. 
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Table 1 Perceived Benefits of Closed-Loop Therapy 
Benefit 
arising from 
closed-loop 
system usage 
Sample key-words used by participants Number of 
participants 
mentioning 
benefit* (%) 
Peace of mind Mental freedom, relaxing, less worried, easy, does everything for 
you, don’t have to think about diabetes, reassuring for others, relying 
on machine, confident, less diabetic, freeing, less guilty about baby, 
liberating 
14 (87.5) 
Wonderment 
at new 
technology 
Exciting, interesting, cool, positive, impressed, life-changing, 
fantastic, intuitive, optimistic, great, amazing, incredible, fascinating 
13 (81.3) 
Superior 
glycaemic 
control  
Improved, good job, brilliant, really happy, much better, 95% better, 
pretty good, smoothed highs out, tighter 
12 (75) 
Smartphone 
interface 
experiences 
User-friendly, intuitive, easy to use, fine, talked to other devices well, 
helpful, useful 
11 (68.8) 
CGM-related 
benefits (other 
than learning 
experiences) 
Accurate, helpful, reassurance, easy, insight, continuous, constant 9 (56.3) 
Flexible 
lifestyle 
 
Easier, enjoying eating, fewer finger-pricks, convenient, others used 
to seeing phones in public, nice feeling, independence  
9 (56.3) 
 
Learning 
experiences 
Helpful, useful, more informed, better clinic appointments, 
surprising, better than health professionals 
9 (56.3) 
Alarms  Useful, fine, confident, helpful, more aware 7 (43.8) 
Study insulin 
pump 
Fine, good, really good, straightforward 6 (37.5) 
Bodily 
assimilation of 
devices 
Didn’t feel any different, part of me, got used to it, intuitive 5 (31.3) 
Sleep 
 
Better, comfort, not worrying 5 (31.3) 
Ease of 
maintenance 
and logistics  
Not too bad, not a huge problem, not any different from normal 3 (18.8) 
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Table 2 Perceived Burdens arising from Closed-Loop Therapy 
Burden arising 
from closed-loop 
system usage 
Sample key-words used by participants Participants 
mentioning 
burden (%) 
Technical 
glitches (non-
CGM) 
Connectivity loss, temperature errors, disconnects, reverts to open 
loop, error messages, system freezes, battery life, phone dies 
16 (100) 
Technical 
glitches (CGM) 
Inaccurate, time lag, insertion problems, calibration difficulties, 
dodgy sensor batch, compression events, reversion to open-loop 
14 (87.5) 
System bulk Nuisance, bulky, a pain, inconvenient, quite big, difficult, 
cumbersome, many components, chunky 
13 (81.3) 
Maintenance and 
logistical 
requirements 
Annoying, hard work, overwhelmed, need knowledge to use 
properly, full-time job, self-care responsibility 
12 (75) 
Alarms Frustrating, annoying, unhelpful, sleep problems, constant bleeping 11 (68.8) 
Cautious 
algorithm leading 
to suboptimal 
control 
Frustrating, rubbish, slightly worse, random, surprising, not 
aggressive enough 
8 (50) 
Need for human 
input (bolusing) 
Bolus administration, meal announcements, difficult 7 (43.8) 
 
Study insulin 
pump 
 
Old school, annoying, casing cracked, backwards, fiddly, noisy 7 (43.8) 
 
System visibility Unattractive, visible, odd looks, cyborgs, annoying, hiding 7 (43.8) 
Adhesive 
problems 
Hurts, irritation, annoying 5 (31.3) 
Challenges of 
surrendering 
control to 
technology 
Frustrating, apprehensive, inflexible, controlled, odd, frightening, 
weird 
5 (31.3) 
Anxiety arising 
from system use 
Panic, lack of freedom 4 (25) 
Exercise Frustrating, hard work, stopped exercise 3 (18.8) 
Addiction to 
system 
24 hours a day 1 (6.3) 
Deskilling Reliant  1 (6.3) 
Smartphone 
interface 
experiences 
Slow, frustrating 1 (6.3) 
 
